ZNF384

Across TCGA pan-cancer cohorts, ZNF384 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZNF384 data layer compared with 27 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in thyroid carcinoma (THCA), where higher ZNF384 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZNF384 expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

THCA, SARC, and PRAD are the cancer types where ZNF384 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THCA	DFS	Median	All	0.049	0.841	<.001	24	view →
SARC	DFS	Median	All	0.109	0.591	.020	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
HNSC	DFS	Median	All	0.292	0.605	.049	3	view →
STAD	DFS	Median	II,III,IV	1.000	0.373	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ZNF384–THCA (DFS)

Open the THCA breakdown →